Nanobiotix (NASDAQ:NBTX) Shares Up 6.7% – Time to Buy?

Nanobiotix S.A. (NASDAQ:NBTX)’s share price rose 6.7% during mid-day trading on Wednesday . The stock traded as high as $3.47 and last traded at $3.29. Approximately 38,075 shares were traded during trading, an increase of 71% from the average daily volume of 22,202 shares. The stock had previously closed at $3.08.

Analyst Upgrades and Downgrades

Separately, UBS Group raised shares of Nanobiotix to a “hold” rating in a research report on Monday, February 17th.

Nanobiotix Stock Up 6.7 %

The stock’s 50 day moving average is $3.42 and its 200 day moving average is $4.00.

Hedge Funds Weigh In On Nanobiotix

Institutional investors and hedge funds have recently made changes to their positions in the company. Millennium Management LLC bought a new stake in Nanobiotix in the 4th quarter valued at $39,000. Jane Street Group LLC bought a new stake in shares of Nanobiotix in the fourth quarter valued at about $73,000. Geode Capital Management LLC bought a new stake in shares of Nanobiotix in the fourth quarter valued at about $29,000. Finally, OLD Mission Capital LLC acquired a new position in shares of Nanobiotix in the fourth quarter valued at about $139,000. Institutional investors and hedge funds own 38.81% of the company’s stock.

About Nanobiotix

Nanobiotix SA, a clinical-stage biotechnology, focuses on developing product candidates for the treatment of cancer and other unmet medical needs. Its lead product candidate is NBTXR3, a sterile aqueous suspension of crystalline hafnium oxide nanoparticles used for the treatment of soft tissue sarcoma, head and neck cancers, liver cancers, prostate cancer, pancreatic cancer, esophageal cancer, rectal cancer, and non-small cell lung cancer.